Tweets
de Boysson et al. Beta-blockers may prevent aortic dilation in LVV GCA (0% vs 23%). 65 patients, retrospective , and patients were on beta-blockers for other reasons, but thought-provoking @rheumnow #ACR22 Abstr#0477 https://t.co/AVmIwCk3LV https://t.co/Plv5tcN5mR
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Auroux et al report differential micro-RNA signatures in hand OA compared to controls (15 upregulated, 4 downregulated). No difference erosive vs non-erosive hand OA. May elucidate pathophys but also ?treatment target @rheumnow #ACR22 Abstr#0023 https://t.co/Kzv8WDmHRU https://t.co/4nCuTjvR6d
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Gisslander et al Cluster analysis in AAV in Sweden. 5 groups. 2 PR3+ groups, younger, ENT or nerve involvement - good prognosis. 2 older MPO+ groups - lung or renal involvement - worse prognosis. @rheumnow #ACR22 Abstr#0433 https://t.co/itokBTOujS https://t.co/PG6CpZvN1a
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
#abst0129 #acr22 @rheumnow analysis 6 Euro studies of active RA, PsA, axSpA &secondary failure of TNFαi showed golimumab to be effective 2nd-line Rx. GLM show improvement in Dis activity, QoL& high retention( 2/3 pts on Rx after 12mo). https://t.co/6OeKwJpqQp
Olga Petryna @DrPetryna ( View Tweet )
3 years 8 months ago
Kirby et al @colmkirby22 . Subclinical GCA in newly diagnosed PMR. 25 patients. 20% had LVV on US - TA in all, axillary in 1. All 5 developed clinical GCA over 1 year. @rheumnow #ACR22 Abstr#0478 https://t.co/xMMjH2XCUD https://t.co/JEtwEGTEbP
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Papo et al. EGPA. Predictors of relapse: Age at diagnosis GC dependent asthma before EGPA (HR1.57), Arthralgia(HR 1.27),myocarditis(HR1.74),peripheral neuropathy(HR 1.39) MPO-ANCA(HR1.56), baseline eosinophil count @rheumnow #ACR22 Abstr#0432 https://t.co/Yq6Eomr9z0 https://t.co/8CYOYROi72
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Genicular nerve block for knee OA - exciting short-term symptomatic option, great Australian work on the Ignite stage. Looking forward to seeing more!
ABST1892 Shanahan et al @Flinders #ACR22 @RheumNow https://t.co/ssYoXj4wjg
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
Ab0373 #ACR22 SpA-U
@ChristianaSiero:
42 pts w/ SpA-r uveitis, 190 attacks
Uveitis more severe: smoking, axial & peripheral involvement, BASDAI>4, HLA-B27+, female, CRP elevation, h/o bilateral ocular involvement
Less severe: shorter disease evolution, nml vit D
@Rheumnow
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Important! Abst#2054 A Novel Treatment Response Measure (TRM) for SLE Clinical Trials is being developed, an international collaboration by clinical-academics, regulatory experts, pt reps, & industry. It will impact how clinical trials will be designed. #ACRbest @rheumnow #ACR22
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
Be careful what you look for? Serum from 32 ACPA+ Pts and 30 ACPA neg all w #rheumatoidarthritis had multiplexed Ab- screening microarray w 1600+ antibodies. Novel Abs were identified in each group vs healthy controls. What does this mean? #ACR22 abst#0256 @RheumNow @ACRheum https://t.co/mqL8kuUkxY
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
#ACR22 @RheumNow how do you approach treatment choices for your PsA pts on TNF inhibitors after first TNFi failure?
Olga Petryna @DrPetryna ( View Tweet )
3 years 8 months ago
Large Korean study on risk of infections in ankylosing spondylitis patients receiving biologics.
Infection incidence risk 26 events/1000 PY
Resp infection most common, 2nd zoster
Heart disease, high DA, DM, current bDMARD use = risk factors
Abs#0372 @RheumNow #ACR22
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 8 months ago
